Navigation Links
Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
Date:3/5/2008

lopment candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including the expected properties and benefits of RDEA806 and RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
2. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
3. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
4. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
7. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
8. Ardea Biosciences Announces Changes to Research Management
9. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
10. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
11. DARA BioSciences, Inc. Announces Appointment of New Director to Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ), ... solutions for the detection of foodborne pathogens, announced plans ... of 2015 on May 7, 2015 after the close ... also host a conference call at 4:30 p.m. Eastern ... quarter financial results. During the conference call, material information ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has commenced an underwritten ... expects to grant the underwriters a 30-day option to ... shares of common stock offered in the public offering. ... can be no assurance as to whether or when ...
(Date:4/30/2015)... YORK , April 30, 2015 The following ... Board of Directors of China Cord Blood Corp (NYSE: ... the special committee of the independent directors of China Cord ... low privatization offer of $6.40 per share from Golden Meditech ... at $6.40 per share would greatly benefit Golden Med and ...
(Date:4/30/2015)... April 30, 2015  Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics including high value and ... of its previously announced underwritten public offering of ... public offering price of $15.50 per share. This ... of their option to purchase up to 750,000 ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... BNVI ), a leader in the discovery and development ... and cancer, today announced,that Tom Chesterman, SVP and CFO of ... The presentation will take place on October 11, 2007 ... CA. A live audio web cast and slide presentation ...
... MEETING, Pa., Oct. 5 Genaera,Corporation (Nasdaq: ... be,presenting at two upcoming conferences, Biotech 2007 in ... in San Francisco on October,9-11, 2007. Henry ... Scientific,Officer of Genaera, is scheduled to participate in ...
... molecular structure found in seashells, University of Michigan researchers ... but lighter and transparent. , It,s made of ... shares chemistry with white glue. , Engineering professor Nicholas ... material isn,t quite stretchy enough to earn that name. ...
Cached Biology Technology:Genaera to Present at Biotech 2007 and BIO InvestorForum 2Genaera to Present at Biotech 2007 and BIO InvestorForum 3U-M research: New plastic is strong as steel, transparent 2
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... say they have assembled more completely the string of ... to imitate their owners and other sounds. The ... genome using a new technology, single molecule sequencing, and ... The team also decoded hard-to-sequence genetic material from corn ...
... known to both eat and inhabit dead whale skeletons ... unique ability to release bone-melting acid, scientists at Scripps ... recently discovered. The work is being presented at the ... Dr Sigrid Katz, a postdoctoral researcher working ...
... the average three year life span of a common rat, ... rat, a subterranean rodent native to East Africa, is impressive. ... rodent shows little decline due to aging, maintaining high activity, ... Now a collaborative of researchers in Israel and the United ...
Cached Biology News:DNA sequenced for parrot's ability to parrot 2DNA sequenced for parrot's ability to parrot 3Acid-wielding worms drill through bones at the bottom of the sea 2Naked mole rat may hold the secret to long life 2
Human ABCG2 MAb (Clone 5D3)...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
... technology incorporating the sophisticated DirectDrive architecture ... new Varian NMR System is undeniably ... ,The Varian NMR System features parallel ... channel, providing pulse sequence programming power ...
Biology Products: